Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)

Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline, Annamycin, has demonstrated both safety and promising early activity across multiple clinical studies with potential to be an effective treatment across multiple oncology indications Recent independent report from cardiology expert concluded Annamycin has no evidence of cardiotoxicity to date in a total of 42 subjects across three of the Company’s Annamycin clinical trials Granted FDA Fast Track and Orphan Drug designation for AML and STS lung mets HOUSTON, Dec. 15, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today provided an update on its clinical programs evaluating Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. These updates were recently presented during a reception for potential investigators held outside of the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.

The release as fetched from its publisher. moleculin.com ↗